acquired
Stage
2003
Founded
3
Investors
About
Ambrx is a clinical-stage biopharmaceutical company focused on discovering and developing next-generation antibody-drug conjugates (ADCs) using its proprietary expanded genetic code technology platform.
Explore Ambrx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.